ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

EP2/EP4/DP1 Antagonist OKN4395

Its studies are mostly in Sarcoma, led by Epkin.

Furthest: phase 1, since Jan 13, 20251 company-led study, 1 open or runningNext primary completion: Jul 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Epkin11 open or runningphase 1since Jan 13, 2025Jan 13, 2025Jul 2028phase 1 · NCT06789172

Also a collaborator on its studies: Precision For Medicine.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 13, 2025First study: phase 1 study in SarcomaFirst studyNCT06789172 · 146 planned · United States, Australia, United Kingdom

Ahead

  1. Jul 2028Primary completion: phase 1 study in SarcomaNCT06789172

TargetBeta

PTGER4 →read by rule
“An orally bioavailable, triple antagonist of the human prostaglandin E2 receptor subtypes 2 (EP2) and 4 (EP4), and the prostaglandin D2 receptor (DP1), ”NCIt, by rule

Other programs on PTGER4

ProgramCompanyFurthest phaseStudies
EP4 Receptor Antagonist YY001rulechongqing-claruvis-pharmaceutical-co-ltdphase 36
BMS-986310ruleOno Pharmaceuticalphase 36

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06789172Sarcoma · United States, Australia, United Kingdom1RecruitingJul 2028146

How it is read

Names in the registry

  • “OKN4395”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.